Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Identification of Cystathionine gamma-lyase Inhibitor - Potential Therapeutic for Clear Cell Ovarian Cancer

EF 2023-24

Résumé
Each year over 207,000 people die due to ovarian cancer. People with late-stage Clear-Cell ovarian cancer (CCOC) are especially resistant to traditional chemotherapies and have the worst outcome of survival compared to other types of ovarian cancer. The protein called cysathionine gamma-lyase (CTH) is highly produced only in the CCOC subtype and has been found to relate to the ability of the tumour to spread to other body organs. The cancer cells spread less when the CTH protein is genetically removed, but can grow much faster, and are more responsive to chemotherapy drug called cisplatin. This study hypothesizes that targeting CTH, either along or in combination with chemotherapy or radiotherapy, may be a good way to treat cancer. There are drugs on the market that prevent CTH from functioning, but these drugs also slow down another protein in the body called cystathionine beta-synthase. Since there are no drugs that specifically target CTH, this study uses a computer-based program and found 233 compounds that may interact with CTH. This study will test these compounds in CCOC cells and monitor the change in cancer cell growth along or with chemotherapy or radiotherapy. The compounds that show an increase in growth will go through more detailed test to see their effects on CTH. The change of protein or RNA in cancer cells in response to the compounds in different treatments will be measured by various methods. The best compounds will be tested in animal mouse models to monitor their effects on the spread of cancer cells. The outcome of this study will improve cancer survival and quality of life, and reduce the cost of CCOC treatment in the long run.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506409
Name
Li Yuqin
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of Cystathionine gamma-lyase Inhibitor - Potential Therapeutic for Clear Cell Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clear Cell Ovarian Cancer; Combination Treatment; Cystathionine Gamma-Lyase; Inhibitor Screening; Metastasis; Microenvironmental Stresses
Abstract
Each year over 207,000 people die due to ovarian cancer. People with late-stage Clear-Cell ovarian cancer (CCOC) are especially resistant to traditional chemotherapies and have the worst outcome of survival compared to other types of ovarian cancer. The protein called cysathionine gamma-lyase (CTH) is highly produced only in the CCOC subtype and has been found to relate to the ability of the tumour to spread to other body organs. The cancer cells spread less when the CTH protein is genetically removed, but can grow much faster, and are more responsive to chemotherapy drug called cisplatin. This study hypothesizes that targeting CTH, either along or in combination with chemotherapy or radiotherapy, may be a good way to treat cancer. There are drugs on the market that prevent CTH from functioning, but these drugs also slow down another protein in the body called cystathionine beta-synthase. Since there are no drugs that specifically target CTH, this study uses a computer-based program and found 233 compounds that may interact with CTH. This study will test these compounds in CCOC cells and monitor the change in cancer cell growth along or with chemotherapy or radiotherapy. The compounds that show an increase in growth will go through more detailed test to see their effects on CTH. The change of protein or RNA in cancer cells in response to the compounds in different treatments will be measured by various methods. The best compounds will be tested in animal mouse models to monitor their effects on the spread of cancer cells. The outcome of this study will improve cancer survival and quality of life, and reduce the cost of CCOC treatment in the long run.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Yuqin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~